Cargando…

Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation

Outcomes of patients with pulmonary arterial hypertension (PAH) may be associated with social determinants of health (SDOH) and other baseline patient characteristics. At present, there is no prognostic model to predict important patient outcomes in PAH based on SDOH. Utilizing information from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grinnan, Dan, Kang, Le, DeWilde, Christine, Badesch, David, Benza, Raymond, Bull, Todd, Chakinala, Murali, DeMarco, Teresa, Feldman, Jeremy, Ford, Hubert J., Klinger, James, McConnell, John, Rosenzweig, Erika B., Sager, Jeffrey, Shlobin, Oksana, Zamanian, Roham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330350/ https://www.ncbi.nlm.nih.gov/pubmed/35911181 http://dx.doi.org/10.1002/pul2.12120

Ejemplares similares

Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
por: Minhas, Jasleen, et al.
Publicado: (2021)

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
por: Fakhri, Shoaib, et al.
Publicado: (2020)

Impact of the COVID‐19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry
por: Mayer, Megan, et al.
Publicado: (2023)

The Production of the PHAR-QA Competence Framework †
por: Atkinson, Jeffrey
Publicado: (2017)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic
por: Ryan, John J., et al.
Publicado: (2020)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Corrigendum for health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry
por: Minhas, J., et al.
Publicado: (2022)

The Second Round of the PHAR-QA Survey of Competences for Pharmacy Practice
por: Atkinson, Jeffrey, et al.
Publicado: (2016)

The heterogeneous pharmacological medical biochemical network PharMeBINet
por: Königs, Cassandra, et al.
Publicado: (2022)

Curriculum Mapping of the Master’s Program in Pharmacy in Slovenia with the PHAR-QA Competency Framework
por: Gmeiner, Tanja, et al.
Publicado: (2017)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
por: DuBrock, Hilary M., et al.
Publicado: (2021)

Antiallodynic effect of PhAR‐DBH‐Me involves cannabinoid and TRPV1 receptors
por: Quiñonez‐Bastidas, Geovanna Nallely, et al.
Publicado: (2020)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

Microbial polyhydroxyalkanote synthesis repression protein PhaR as an affinity tag for recombinant protein purification
por: Zhang, Shuang, et al.
Publicado: (2010)

Characterization of hypotensive and vasorelaxant effects of PHAR-DBH-Me a new cannabinoid receptor agonist
por: López-Canales, Oscar Alberto, et al.
Publicado: (2022)

A Novel Nucleic Lateral Flow Assay for Screening phaR-Containing Bacillus spp.
por: Wint, Nay Yee, et al.
Publicado: (2021)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

The PHAR-QA Project: Competency Framework for Pharmacy Practice—First Steps, the Results of the European Network Delphi Round 1
por: Atkinson, Jeffrey, et al.
Publicado: (2015)

Bradyrhizobium diazoefficiens USDA110 PhaR functions for pleiotropic regulation of cellular processes besides PHB accumulation
por: Nishihata, Shogo, et al.
Publicado: (2018)

Intravenous Vitamin C Administered as Adjunctive Therapy for Recurrent Acute Respiratory Distress Syndrome
por: Bharara, Amit, et al.
Publicado: (2016)

A transferable heterogeneous two-hybrid system in Escherichia coli based on polyhydroxyalkanoates synthesis regulatory protein PhaR
por: Wang, Zhi-Hui, et al.
Publicado: (2011)

Author rebuttal to response regarding “Letter to the Editor regarding ‘Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?’”
por: Horn, Evelyn, et al.
Publicado: (2020)

Riociguat: Clinical research and evolving role in therapy
por: Klinger, James R., et al.
Publicado: (2020)

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design
por: Benza, Raymond L., et al.
Publicado: (2022)

Mutagenesis of PhaR, a Regulator Gene of Polyhydroxyalkanoate Biosynthesis of Xanthomonas oryzae pv. oryzae Caused Pleiotropic Phenotype Changes
por: Long, Ju-Ying, et al.
Publicado: (2018)

Bridging the gap between physical and mental illness in community pharmacy (PharMIbridge): protocol for an Australian cluster randomised controlled trial
por: Wheeler, Amanda J, et al.
Publicado: (2020)

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
por: Rahaghi, Franck F., et al.
Publicado: (2022)

Monitoring and kinetic analysis of the molecular interactions by which a repressor protein, PhaR, binds to target DNAs and poly[(R)-3-hydroxybutyrate]
por: Yamada, Miwa, et al.
Publicado: (2013)

Bridging the gap between physical and mental illness in community pharmacy (PharMIbridge): Implementation of a cluster-RCT during the COVID-19 pandemic
por: Hu, Jie, et al.
Publicado: (2023)

Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction
por: Perez, Vinicio A. de Jesus, et al.
Publicado: (2012)

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care
por: Lee, Joshua D., et al.
Publicado: (2020)

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Pilots for Healthy and Active Ageing (PHArA-ON) Project: Definition of New Technological Solutions for Older People in Italian Pilot Sites Based on Elicited User Needs
por: D’Onofrio, Grazia, et al.
Publicado: (2021)

A search for second-generation leptoquarks in $pp$ collisions at $\sqrt{s}$ = 7 TeV with the ATLAS detector
por: DeWilde, Burton
Publicado: (2018)

Impact of a Pharmacist-included Mobile Geriatrics team intervention on potentially inappropriate drug prescribing: protocol for a prospective feasibility study (PharMoG study)
por: Pagès, Arnaud, et al.
Publicado: (2020)

Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011
por: Tsai, Halley, et al.
Publicado: (2019)

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
por: Elliott, C. Gregory, et al.
Publicado: (2019)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension
por: Taylor, Shalina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6he4vah3i3g8nd02p8rhl73j95